Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds
Summary
- With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina.
- The global DNA sequencing market is expected to grow at a CAGR of 9% from 2024 and 2028, which is a positive aspect for Illumina.
- Illumina has reported higher gross profit margins than its peers, which reflects that its core business is profitable.
- The U.S.government's decision to significantly reduce its expenses on its healthcaresystem will have a negative impact on Illumina.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.